Table 2.
Antipsychotic medication | mg per day/injection | no. of patientsd |
---|---|---|
Oral | ||
Amisulpridec | 116.3 | 1 |
Aripiprazoleb | 4 | 7 |
Chlorprothixenec | 83.3 | 2 |
Clozapinec | 66.7 | 6 |
Olanzapineb | 3 | 9 |
Quetiapineb | 60 | 5 |
Zuclopenthixolc | 8.3 | 3 |
Depot a | ||
Paliperidoneb | 15 | 2 |
Perphenazine decanoatec | 41.4 | 1 |
Risperidoneb | 10 | 3 |
Zuclopenthixol decanoatec | 66.4 | 4 |
aDepot antipsychotics were first converted to oral equivalencies of the same drug using suggested equivalencies based on studies of oral to depot switch77 or manufacturer’s recommendation78,79 and then converted to CPZ equivalents (see note b and c). For perphenazine decanoate we used the average minimum effective dose of perphenazine decanoate80 and equated it with the lowest recommended target dose of oral perphenazine49 and then converted to CPZ equivalents (see note c). bFor the second-generation antipsychotics, we used Leucht et al.48 to convert to CPZ equivalents when possible except for clozapine where the conversion result was highly questionable. cFor other antipsychotics (including clozapine), we used Gardner et al.49 to convert to CPZ equivalents. dEighteen patients were taking one antipsychotic, 11 were taking two and one was taking three.